I absolutely just love the innovation. I love to be in the lab – I get a buzz from that’

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

While COVID-19 remains a top research priority globally for government and nonprofit entities in partnership with biopharma companies, deal activity also is heavily focused on other infectious diseases, such as smallpox and influenza. In fact, only about half

As global temperatures have gone up, so too have outbreaks of many infectious illnesses. Climate change has exacerbated 218 out of 375 conditions Climate change is constantly in the news these days and for good reason. The report

London-listed Poolbeg Pharma “is entering a very exciting” phase, its chief executive said on Monday, after the company received human trial approval for its influenza drug in the UK in July. Unaudited interim results published by the company

AI Magazine explores the importance of artificial intelligence (AI) as the healthcare industry continues to digitise and utilise tech for drug discovery Recently MarketsandMarkets released an exclusive report on artificial intelligence (AI) in drug discovery and found that the

Last month, Alphabet’s artificial intelligence subsidiary, DeepMind, stunned the world of science by presenting something truly spectacular: a snapshot of nearly every existing protein on Earth — 200 million of them. This machine-learning feat could speed the creation

Influenza is a highly contagious respiratory illness caused by influenza virus. There are two main types of human influenza viruses: A and B. There are also many sub-types and strains. Flu can occur throughout the year but is

Poolbeg Pharma has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment

Poolbeg Pharma has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment

London-listed Poolbeg Pharma has received regulatory approval in the UK to proceed with human clinical trials of its influenza drug POLB 001. The company, which spun out from Dublin-listed pharmaceutical services business Open Orphan last year, said the